BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Sunesis Pharmaceuticals, Inc. (“Sunesis” or the “Company”) (NASDAQ: SNSS) investors concerning the Company and its officers’ potential violation of federal securities laws.
Sunesis is a biopharmaceutical company that focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML).
On May 1, 2017, Sunesis disclosed that the Company will be pulling its European Marketing Authorization Application for vosaroxin, the Company's lead product candidate for relapsed/refractory AML. Sunesis informed investors that the decision comes after recent dealings with the European Medicine Agency's Committee for Medicinal Products for Human Use revealed that the committee was likely to approve a negative opinion in its review of the product.
On this news, shares of Sunesis fell $0.69 per share, or almost 20%, to close at $2.97 per share on May 2, 2017.
If you purchased Sunesis securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to email@example.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.